FDA Shouldn't Require Monitoring Of Third Parties In REMS, Industry Says
Executive Summary
FDA's requirements for Risk Evaluation and Mitigation Strategies should focus on sponsors' activities and not the behavior of third parties, industry tells the agency in comments on a draft guidance
You may also be interested in...
With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays
The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized
With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays
The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized
Generics Should Get REMS Exemption For Sample Collection, GPhA Says
FDA should create a system to allow generic firms that want to develop ANDAs for products in closed distribution systems to obtain samples from the brand sponsors, the Generic Pharmaceutical Association says